Oarsman Capital, Inc. Abb Vie Inc. Transaction History

Oarsman Capital, Inc.

$533 Million
Q3 2024

A detailed history of Oarsman Capital, Inc. transactions in Abb Vie Inc. stock. As of the latest transaction made, Oarsman Capital, Inc. holds 19,088 shares of ABBV stock, worth $3.24 Million. This represents 0.71% of its overall portfolio holdings.

Number of Shares

19,088

Previous 18,782 1.63%

Holding current value

$3.24 Million

Previous $3.22 Million 17.01%

% of portfolio

0.71%

Previous 0.72%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 08, 2024	BUY	$163.84 - $199.33 $50,135 - $60,994	306 Added 1.63%	19,088 $3.77 Million
Q2 2024 Aug 12, 2024	BUY	$154.79 - $180.76 $190,701 - $222,696	1,232 Added 7.02%	18,782 $3.22 Million
Q1 2024 May 15, 2024	SELL	$159.82 - $182.1 $917,047 - $1.04 Million	-5,738 Reduced 24.64%	17,550 $3.2 Million
Q4 2023 Feb 16, 2024	BUY	$137.6 - $154.97 $109,667 - $123,511	797 Added 3.54%	23,288 $3.61 Million
Q3 2023 Oct 27, 2023	BUY	$133.59 - $154.65 $16,965 - $19,640	127 Added 0.57%	22,491 $3.35 Million
Q2 2023 Aug 10, 2023	SELL	$132.51 - $164.9 $272,838 - $339,529	-2,059 Reduced 8.43%	22,364 $3.01 Million
Q1 2023 May 11, 2023	BUY	$144.61 - $166.54 $67,966 - $78,273	470 Added 1.96%	24,423 $3.89 Million
Q4 2022 Feb 09, 2023	SELL	$138.31 - $165.87 $102,764 - $123,241	-743 Reduced 3.01%	23,953 $3.87 Million
Q3 2022 Nov 10, 2022	BUY	$134.21 - $153.93 $3.31 Million - $3.8 Million	24,696 New	24,696 $3.31 Million
Q2 2022 Aug 10, 2022	SELL	$137.62 - $174.96 $308,956 - $392,785	-2,245 Reduced 8.35%	24,630 $3.77 Million
Q1 2022 May 11, 2022	SELL	$131.98 - $163.75 $210,772 - $261,508	-1,597 Reduced 5.61%	26,875 $4.36 Million
Q4 2021 Feb 10, 2022	SELL	$107.43 - $135.93 $213,570 - $270,228	-1,988 Reduced 6.53%	28,472 $3.86 Million
Q3 2021 Nov 12, 2021	SELL	$106.4 - $120.78 $2,979 - $3,381	-28 Reduced 0.09%	30,460 $3.29 Million
Q2 2021 Aug 12, 2021	SELL	$105.21 - $117.21 $142,243 - $158,467	-1,352 Reduced 4.25%	30,488 $3.43 Million
Q1 2021 May 12, 2021	SELL	$102.3 - $112.62 $512,625 - $564,338	-5,011 Reduced 13.6%	31,840 $3.45 Million
Q4 2020 Feb 11, 2021	SELL	$80.49 - $108.67 $182,229 - $246,028	-2,264 Reduced 5.79%	36,851 $3.95 Million
Q3 2020 Nov 12, 2020	SELL	$85.91 - $100.83 $87,284 - $102,443	-1,016 Reduced 2.53%	39,115 $3.43 Million
Q2 2020 Aug 13, 2020	BUY	$73.37 - $98.18 $1.43 Million - $1.92 Million	19,555 Added 95.04%	40,131 $3.94 Million
Q1 2020 May 13, 2020	SELL	$64.5 - $97.79 $1.04 Million - $1.58 Million	-16,123 Reduced 43.93%	20,576 $1.57 Million
Q4 2019 Feb 13, 2020	BUY	$72.13 - $90.25 $139,138 - $174,092	1,929 Added 5.55%	36,699 $3.25 Million
Q3 2019 Nov 12, 2019	BUY	$62.98 - $75.72 $118,843 - $142,883	1,887 Added 5.74%	34,770 $2.63 Million
Q2 2019 Aug 13, 2019	SELL	$65.7 - $83.98 $4,270 - $5,458	-65 Reduced 0.2%	32,883 $2.39 Million
Q1 2019 May 14, 2019	SELL	$77.14 - $90.79 $1 Million - $1.18 Million	-12,989 Reduced 28.28%	32,948 $2.66 Million
Q4 2018 Feb 13, 2019	BUY	$77.85 - $96.01 $84,622 - $104,362	1,087 Added 2.42%	45,937 $4.24 Million
Q3 2018 Nov 07, 2018	BUY	$88.91 - $98.84 $12,803 - $14,232	144 Added 0.32%	44,850 $4.24 Million
Q2 2018 Aug 10, 2018	BUY	$89.78 - $106.23 $139,607 - $165,187	1,555 Added 3.6%	44,706 $4.14 Million
Q1 2018 May 14, 2018	SELL	$92.01 - $123.21 $112,252 - $150,316	-1,220 Reduced 2.75%	43,151 $4.08 Million
Q4 2017 Feb 08, 2018	SELL	$89.56 - $98.21 $31,077 - $34,078	-347 Reduced 0.78%	44,371 $4.29 Million
Q3 2017 Nov 13, 2017	BUY	$69.85 - $89.22 $3.12 Million - $3.99 Million	44,718	44,718 $3.97 Million

Others Institutions Holding ABBV

# of Institutions

3,817

Shares Held

1.25B

Call Options Held

13M

Put Options Held

10M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $300B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Oarsman Capital, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Oarsman Capital, Inc. with notifications on news.

Account

Oarsman Capital, Inc. Abb Vie Inc. Transaction History